In This Article:
PARIS, December 04, 2024--(BUSINESS WIRE)--Regulatory News:
ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, is proud to announce the launch of its new vision and strategy under the brand "ALIKO SCIENTIFIC" (www.alikoscientific.com). This pivotal development introduces a renewed corporate identity and business vision, marking the Group’s transformation into a global hub for next-generation oncology diagnostics.
ALIKO SCIENTIFIC: A New Era for Cancer Diagnostics
Guided by the motto "Next Generation Cancer Diagnostics", ALIKO SCIENTIFIC embodies the Group’s renewed vision and its commitment to revolutionize cancer detection and treatment. By integrating cutting-edge technologies with top scientific expertise, the Group aims at establishing itself as an international player of excellence, drawing on the acquisition of Hospitex in early 2024.
The new corporate identity, ALIKO SCIENTIFIC, draws inspiration from the ticker "ALIKO," under which Ikonisys SA is listed on the Paris Stock Exchange (Euronext Growth Paris) and replaces Ikonisys SA. Through this new identity, the Company evolves into a corporate hub responsible for the strategic, financial, and operational management of innovative companies and technologies dedicated to oncology diagnostics.
The global cancer diagnostics market, valued at $136 billion in 2022, is projected to grow at a CAGR of 9% over the next decade, reaching $324 billion by 20321. By leveraging the synergies between Ikonisys and Hospitex technologies, the Group is well-positioned to capitalize on this growth by offering integrated solutions rather than standalone products.
Business Vision
The acquisition of Hospitex International in 2024 marked a turning point for Ikonisys SA, strengthening its strategic position in oncology diagnostics. Under the ALIKO SCIENTIFIC brand, the Group is poised to become a global leader in next-generation cancer diagnostics, organized as follows:
-
ALIKO SCIENTIFIC: The corporate hub, coordinating R&D, business development and partnerships, financial activities and strategic acquisitions (www.alikoscientific.com);
-
Ikonisys: A leader in automated molecular cancer diagnostics offering advanced, highly precise microscopy imaging and AI-driven software solutions (www.ikonisys.com); and
-
Hospitex: A world class player in precision cytology, recognized for its innovative sample standardization technology (www.hospitex.com).